Computational algorithm-driven evaluation of monocytic myeloid-derived suppressor cell frequency for prediction of clinical outcomes.
about
Clinical utility of nivolumab in the treatment of advanced melanomaNovel technologies and emerging biomarkers for personalized cancer immunotherapyPaving the Road to Tumor Development and Spreading: Myeloid-Derived Suppressor Cells are Ruling the FateTumor-induced myeloid deviation: when myeloid-derived suppressor cells meet tumor-associated macrophagesClinical Development of Immune Checkpoint Inhibitors.Clinical significance of plasmacytoid dendritic cells and myeloid-derived suppressor cells in melanomaComplexity and challenges in defining myeloid-derived suppressor cellsDNA Methylation-Derived Neutrophil-to-Lymphocyte Ratio: An Epigenetic Tool to Explore Cancer Inflammation and Outcomes.2015 Guidance on cancer immunotherapy development in early-phase clinical studies.Phase I/II Study of Metastatic Melanoma Patients Treated with Nivolumab Who Had Progressed after Ipilimumab.Targeting myeloid-derived suppressor cells with colony stimulating factor-1 receptor blockade can reverse immune resistance to immunotherapy in indoleamine 2,3-dioxygenase-expressing tumorsSummary and Recommendations from the National Cancer Institute's Clinical Trials Planning Meeting on Novel Therapeutics for Non-Muscle Invasive Bladder CancerNivolumab for advanced melanoma: pretreatment prognostic factors and early outcome markers during therapy.Ipilimumab in the treatment of advanced melanoma - a clinical update.On being less tolerant: enhanced cancer immunosurveillance enabled by targeting checkpoints and agonists of T cell activation.Myeloid Derived Suppressor Cells: Fuel the Fire.The future of cancer treatment: immunomodulation, CARs and combination immunotherapy.Biomarkers associated with checkpoint inhibitors.Myeloid-derived suppressor cells as intruders and targets: clinical implications in cancer therapy.A clinical and biological perspective of human myeloid-derived suppressor cells in cancer.Targeting KIT on innate immune cells to enhance the antitumor activity of checkpoint inhibitors.Targeting the tumor microenvironment to improve natural killer cell-based immunotherapies: On being in the right place at the right time, with resilience.Identifying baseline immune-related biomarkers to predict clinical outcome of immunotherapy.Immune biomarkers for chronic inflammation related complications in non-cancerous and cancerous diseases.High Absolute Monocyte Count Predicts Poor Clinical Outcome in Patients with Castration-Resistant Prostate Cancer Treated with Docetaxel Chemotherapy.Immunotherapy of cancers comes of age.Role of Tumor Pericytes in the Recruitment of Myeloid-Derived Suppressor Cells.Increases in Absolute Lymphocytes and Circulating CD4+ and CD8+ T Cells Are Associated with Positive Clinical Outcome of Melanoma Patients Treated with Ipilimumab.Baseline Peripheral Blood Biomarkers Associated with Clinical Outcome of Advanced Melanoma Patients Treated with Ipilimumab.Predictors of responses to immune checkpoint blockade in advanced melanomaBiomarkers for Response of Melanoma Patients to Immune Checkpoint Inhibitors: A Systematic Review.Clinical implication of tumor-associated and immunological parameters in melanoma patients treated with ipilimumab.Transcriptional profiling of whole blood: a rich source of immune biomarkers in cancer.Immune Activation in Early-Stage Non-Small Cell Lung Cancer Patients Receiving Neoadjuvant Chemotherapy Plus Ipilimumab.Tumor immunology and cancer immunotherapy: summary of the 2014 SITC primer.Serial pseudoprogression of metastatic malignant melanoma in a patient treated with nivolumab: a case report.The ratio of HLA-DR and VNN2+ expression on CD14+ myeloid derived suppressor cells can distinguish glioblastoma from radiation necrosis patients.Relationships between lymphocyte counts and treatment-related toxicities and clinical responses in patients with solid tumors treated with PD-1 checkpoint inhibitors.Efficacy and immune activation of ipilimumab in early-stage lung cancer patients.Biomarkers for Immune Checkpoint Inhibitors in Melanoma
P2860
Q26751268-65D112FC-996B-4BE8-8AD2-6017936CABC3Q26770780-ECFFDCA6-0098-4268-A98D-22949956C40EQ26777205-07888C00-94F8-4F5F-BB2B-A72BF0711ADBQ34044797-9676C120-0CC2-467B-AEF0-FDCDF10AAE6CQ34671498-BD824538-DA01-416C-BCDC-8F616828C251Q35078852-B58F677A-394D-4D68-BD9F-388E663ECC92Q35509317-2A9D8ED7-FBFD-4E1A-8441-53B6AB82FCB1Q36222815-34C3CC41-7723-4EC3-B8E8-551A9F7E701EQ36467378-54AA9B7F-F0DF-484D-A1EB-A3CDB10E0494Q36759111-359F6B6B-9441-4CF5-BA80-441D6D9270E8Q36869880-E81EAF8D-486B-485F-A5B2-8CA2C2AFBAC2Q37053820-1F57B4A5-94C5-4F35-9CC3-3581540FBF8CQ37718376-BB3AD3C2-AD4F-4DE5-BAC5-FDCE638B3F56Q38253823-0F8F80C0-6B31-4EEC-8249-F3B8AE516ED1Q38391533-DD875573-1F92-42A1-A907-E586A4BAC2C5Q38613648-A0503D4D-3CD2-40F2-B03E-6755BA0B39EAQ38775177-FF61CFF5-D57F-44A5-A592-4FD4D88280BEQ38819537-4C5BF439-80D5-450A-AABE-11A280DFA32AQ38844417-90F2CCFE-8344-4FB5-A7EA-55046041F579Q38847251-28994228-D1B6-4B9B-85FA-7B8ADF3F4CDEQ38878888-AF2ED7C6-D467-45E4-ACA5-4A36DB363540Q39281940-7B790B9A-8AF3-431A-A1C8-36B668810DBDQ39313889-3290B20A-2297-4DFD-8326-8C4D6930BC69Q39412983-B47EE160-B4CD-47BF-A9E0-AC632AC4F66AQ39641273-F3A5EAA6-89DC-4AF2-A80F-83C18280143FQ40099075-436D5980-69DA-4E7C-BD69-14E1A0039071Q40619105-6A8400D3-96D3-456C-858F-42C644274D9DQ40758666-8F87CE4A-B5F7-4868-9A14-89853AC20F76Q40964128-00918964-1581-4EC1-A808-0BBE664C4C36Q41701241-E2A338F4-885C-4F74-8B92-13D66D6E2718Q42369277-9C557D6A-4C72-413C-8723-EA8727168995Q42968783-F79EC200-E003-4FF3-9F4A-F207AEC2DE41Q43103780-0BC66B63-127E-4A8F-8500-1A3812E3CE0BQ45959320-4C246ED1-FCA1-4210-BEF7-AC2886CCAC65Q46090703-E2439438-AD8D-4C3D-BF4C-9215D42AF8A6Q47096567-B51C2E82-EDD7-4146-9D29-EC83DB0A6327Q48367212-F868292F-A1FE-4D8F-8CDB-AFCE6CAE14E0Q49593797-F3B22627-C20D-4929-8548-816535C82E25Q55709749-D19FE200-B227-4E5A-BF37-A9E12CA9DAC5Q57175477-B8F000B1-0406-48BB-90F2-FA4C3494183E
P2860
Computational algorithm-driven evaluation of monocytic myeloid-derived suppressor cell frequency for prediction of clinical outcomes.
description
2014 nî lūn-bûn
@nan
2014 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Computational algorithm-driven ...... ediction of clinical outcomes.
@ast
Computational algorithm-driven ...... ediction of clinical outcomes.
@en
Computational algorithm-driven ...... ediction of clinical outcomes.
@nl
type
label
Computational algorithm-driven ...... ediction of clinical outcomes.
@ast
Computational algorithm-driven ...... ediction of clinical outcomes.
@en
Computational algorithm-driven ...... ediction of clinical outcomes.
@nl
prefLabel
Computational algorithm-driven ...... ediction of clinical outcomes.
@ast
Computational algorithm-driven ...... ediction of clinical outcomes.
@en
Computational algorithm-driven ...... ediction of clinical outcomes.
@nl
P2093
P2860
P50
P1476
Computational algorithm-driven ...... ediction of clinical outcomes.
@en
P2093
Alexander M Lesokhin
Czrina Cortez
Jedd D Wolchok
Jianda Yuan
Katherine S Panageas
Michael A Postow
Shigehisa Kitano
Teresa Rasalan
P2860
P304
P356
10.1158/2326-6066.CIR-14-0013
P577
2014-05-20T00:00:00Z